In NSCLC, several studies documented variable effects of therapeutic immune-checkpoint inhibitors (pembrolizumab) depending on the percentage of tumor cells expressing PD-L1 (as assessed through immunohistochemistry and using positivity cut-off values of ≥ 1%80,81 or ≥ 50%82. Here, CD274 is linked to non-small cell lung carcinoma.